Oxtellar XR TM Launch Update

Oxtellar XR TM was launched in February 2013 by approximately 75 sales representatives focusing on the top 6 deciles of high prescribing physicians. All major wholesalers and several regional wholesalers in the United States have stocked the product, and the Company has a pharmacy assistance service to assist patients in finding a local pharmacy that can quickly order the product and fill their prescription. To date, Oxtellar XR TM has achieved strong coverage on commercial managed care formularies with more than 120 million commercial lives. Initial feedback from the field, while very early into the launch, has been very positive about Oxtellar XR TM. The Company should be in a much better position to look at prescription data as it gets further into the launch.

2013 Financial Guidance

In order to support both product launches and the continued development of our pipeline, we project cash burn for the year to range from $95 million to $105 million. We believe our cash, cash equivalents, and marketable securities as of December 31, 2012 should be sufficient to fund operations into the fourth quarter of 2013.

Assuming availability of data on rebates and allowances, the Company may be able to report revenue for Oxtellar XR TM prescriptions which are sold in the first quarter in its second quarter financial results.

About Oxtellar XR TM

Oxtellar XR TM is a novel once-daily extended release formulation of oxcarbazepine. It is an antiepileptic drug (AED) indicated for adjunctive therapy in the treatment of partial seizures in adults and in children 6 to 17 years of age. The recommended daily dose for adults is 1200 mg to 2400 mg once per day, and for children 6 to 17 years of age is 900 mg to 1800 mg depending on weight. The product is available in 150 mg, 300 mg and 600 mg extended-release tablets.

For full prescribing and safety information, click here .

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company launched one product for epilepsy, Oxtellar XR TM (extended release oxcarbazepine), and has one tentatively approved product for epilepsy, Trokendi XR TM (extended release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to achieve profitability; the Company's ability to raise sufficient capital to implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's respective PDUFA dates for product candidates and anticipated launch dates for its tentatively approved product; the Company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; and other risk factors set forth from time to time in the Company's SEC filings made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
(in thousands)
  December 31, 2011 December 31, 2012
Cash, cash equivalents and marketable securities $48,544 $88,508
Other current assets  855 3,233
Total current assets  49,399 91,741
Property and equipment, net  1,310 1,421
Deferred financing costs  2,054 89
Other long-term assets  967 738
Total Assets $53,730 $93,989
Accounts payable and accrued expenses $11,763 $10,666
Secured notes payable, current  6,775 11,809
Deferred revenue  232 508
Total current liabilities  18,770 22,983
Secured notes payable, long-term  22,711 11,088
Other liabilities  2,806 2,348
Total Liabilities  44,287 36,419
Total Stockholders' Equity  9,443 57,570
Total Liabilities & Stockholders Equity $53,730 $93,989
(in thousands, except per share data)
   Three months ended   Year ended 
   December 31, 2011   December 31, 2012   December 31, 2011   December 31, 2012 
Revenues $42 $1,090 $803 $1,480
Cost and expenses        
Research and development 7,500 5,150 30,627 23,517
Selling, general and administrative 2,785 8,684 7,928 20,132
Total cost and expenses 10,285 13,834 38,555 43,649
Operating loss (10,243) (12,744) (37,752) (42,169)
Other income (expense):        
Interest income 0 30 31 120
Interest expense (508) (804) (1,866) (3,575)
Other income(expense) 87 6 117 (660)
Loss from continuing operations before income taxes (10,664) (13,512) (39,470) (46,284)
Income tax benefit 16,245 --  16,245 -- 
Income (loss) from continuing operations 5,581 (13,512) (23,225) (46,284)
Income from discontinued operations, net of tax  1,542 --  2,188 -- 
Gain on disposal of discontinued operations, net of tax  74,852 --  74,852 -- 
Income from discontinued operations 76,394 --  77,040 -- 
Net income (loss)  81,975 (13,512) 53,815 (46,284)
Cumulative dividends on preferred stock (858) --  (3,430) (1,143)
Net income (loss) attributable to common shareholders $81,117 ($13,512) $50,385 ($47,427)
Net income (loss) per common share:         
Continuing operations  $2.88 ($0.51) ($16.60) ($2.72)
Discontinued operations  46.64  --   47.99  -- 
Net income (loss) $49.52 ($0.51) $31.39 ($2.72)
Net income (loss) per common share: discontinued        
Continuing operations  $2.34 ($0.51) ($16.60) ($2.72)
Discontinued operations  37.80  --   47.99  -- 
Net income (loss) $40.14 ($0.51) $31.39 ($2.72)
Weighted-average number of common shares:        
Basic 1,638,076 26,626,949 1,605,324 17,440,910
Diluted 2,020,874  26,626,949  1,605,324  17,440,910
CONTACT: Jack Khattar, President & CEO         Gregory S. Patrick, Vice President and CFO         Supernus Pharmaceuticals, Inc.         Tel: (301) 838-2591

If you liked this article you might like

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Anika Up on Strong Analyst Ratings